Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?
- 32 Downloads
The present study was conducted to compare the pattern of brain [18F] FDG uptake in suspected non-Alzheimer’s pathophysiology (SNAP), AD, and healthy controls using 2-deoxy-2-[18F]fluoroglucose ([18F] FDG) positron emission tomography imaging. Cerebrospinal fluid (CSF) biomarkers amyloid-β1-42 peptide (Aβ1-42) and tau were used in order to differentiate AD from SNAP.
The study included 43 newly diagnosed AD patients (female = 23; male = 20) according to the NINCDS-ADRDA criteria, 15 SNAP patients (female = 12; male =3), and a group of 34 healthy subjects that served as the control group (CG), who were found to be normal at neurological evaluation (male = 20; female = 14). A battery of neuropsychological tests was administrated in AD and SNAP subjects; cerebrospinal fluid assay was conducted in both AD and SNAP as well. Brain PET/CT acquisition was started 30 ± 5 min after [18F] FDG injection in all subjects. SPM12 [statistical parametric mapping] implemented in MATLAB 2018a was used for the analysis of PET scans in this study.
As compared to SNAP, AD subjects showed significant hypometabolism in a wide cortical area involving the right frontal, parietal, and temporal lobes. As compared to CG, AD subjects showed a significant reduction in [18F] FDG uptake in the parietal, limbic, and frontal cortex, while a more limited reduction in [18F] FDG uptake in the same areas was found when comparing SNAP to CG.
SNAP subjects show milder impairment of brain [18F] FDG uptake as compared to AD. The partial overlap of the metabolic pattern between SNAP and AD limits the use of [18F] FDG PET/CT in effectively discriminating these clinical entities.
Keywords[18F] FDG Alzheimer, SNAP PET/CT Biomarkers
- [18F] FDG
Positron emission tomography
The authors wish to thank Tiziana Martino (IRCCS Neuromed) for data collection. This work was funded in part by the European Commission Horizon 2020 programme, grant 689209: PICASO, A Personalised Integrated Care Approach for Service Organisations and Care Models for Patients with Multi-Morbidity and Chronic Conditions.
Compliance with ethical standards
Conflict of interest
The authors report no financial disclosures/funding or conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15:1044–53. https://doi.org/10.1016/s1474-4422(16)30125-9.CrossRefGoogle Scholar
- 3.Filippi L, Chiaravalloti A, Bagni O, Schillaci O. (18)F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer’s disease. Am J Nucl Med Mol Imaging. 2018;8:268–81Google Scholar
- 7.Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement. 2013;9:295–301. https://doi.org/10.1016/j.jalz.2012.01.006.CrossRefGoogle Scholar
- 14.Chiaravalloti A, Barbagallo G, Ricci M, Martorana A, Ursini F, Sannino P, et al. Brain metabolic correlates of CSF tau protein in a large cohort of Alzheimer’s disease patients: a CSF and FDG PET study. Brain Res. 2018;1678:116–22. https://doi.org/10.1016/j.brainres.2017.10.016.CrossRefGoogle Scholar
- 15.Chiaravalloti A, Castellano AE, Ricci M, Barbagallo G, Sannino P, Ursini F, et al. Coupled imaging with [(18)F]FBB and [(18)F]FDG in AD subjects show a selective association between amyloid burden and cortical dysfunction in the brain. Mol Imaging Biol. 2018;20:659–66. https://doi.org/10.1007/s11307-018-1167-1.CrossRefGoogle Scholar
- 17.Chiaravalloti A, Koch G, Toniolo S, Belli L, Lorenzo FD, Gaudenzi S, et al. Comparison between early-onset and late-onset Alzheimer’s disease patients with amnestic presentation: CSF and (18)F-FDG PET study. Dement Geriatr Cogn Dis Extra. 2016;6:108–19. https://doi.org/10.1159/000441776.CrossRefGoogle Scholar
- 22.World Medical Association (WMA). Declaration of Helsinki. Amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. WMA Archives, Ferney-Voltaire, France. https://web.archive.org/web/20140101202246/ http://www.wma.net/en/30publications/10policies/b3/. Accessed 24 Oct 2018
- 23.D’Agostino E, Maes F, Vandermeulen D, Suetens P. Atlas-to-image non-rigid registration by minimization of conditional local entropy. Information processing in medical imaging : proceedings of the conference. Inf Process Med Imaging. 2007;20:320–32.Google Scholar
- 27.Lancaster JL, Rainey LH, Summerlin JL, Freitas CS, Fox PT, Evans AC, et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method. Hum Brain Mapp. 1997;5:238–42. https://doi.org/10.1002/(sici)1097-0193(1997)5:4<238::aid-hbm6>3.0.co;2-4.CrossRefGoogle Scholar
- 31.Bailly M, Destrieux C, Hommet C, Mondon K, Cottier JP, Beaufils E, et al. Precuneus and cingulate cortex atrophy and Hypometabolism in patients with Alzheimer’s disease and mild cognitive impairment: MRI and (18)F-FDG PET quantitative analysis using FreeSurfer. Biomed Res Int. 2015;2015:583931. https://doi.org/10.1155/2015/583931.CrossRefGoogle Scholar
- 34.Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40:1122–5. https://doi.org/10.1007/s00259-013-2415-x.CrossRefGoogle Scholar
- 37.Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, et al. Alzheimer disease signature neurodegeneration and APOE genotype in mild cognitive impairment with suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 2017;74:650–9. https://doi.org/10.1001/jamaneurol.2016.5349.CrossRefGoogle Scholar